Form 4 for LYEL Lyell Immunopharma, Inc.
Accepted 2026-06-11 16:07:50 ET · period of report 2026-06-10 · accession 0001959742-26-000002 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026-06-11 16:07 | 2026-06-10 | LYEL | Shook David | Chief Medical Off | S - Sale | $12.64 | -1,977 | 20.9K | -9% | -$25.0K |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2026-06-10 | S | D | 1,977 | $12.64 | 20,923 | D | — | — | (F1) Shares automatically sold to cover tax withholding obligation from settlement of vested restricted stock units. (F2) Includes 1,000 shares acquired on May 18, 2026 under the Issuer's 2021 Employee Stock Purchase Plan. |